Clay Siegall is a renowned scientist who has been focused on conducting research to determine cancer cures. He is one of the co-founders of Seattle Genetics Company and also serves it as president and chairperson. The organization has been focused on creating new treatments for cancer, and it was founded in 1998. Siegall is highly skilled and experienced in the field. He has been supporting his company to focus on scientific innovations that can help in curing cancer patients. Clay has excellent administration skills and has guided Seattle Genetics Company to be productive. The firm has presently developed antibody-drug conjugates that have been essential in the treatment of cancer.
Clay has strived to ensure that his company is permitted to participate in different technologies such as Roche, AbbVie, Pfizer, and GlaxoSmithKline. In 2014, he was chosen by Ultragenyx to serve as a member of its board. Dr. Siegall had worked for various organizations before he established Seattle Genetics Company. As from 1991 to 1997, he served as an employee of the Bristol-Myers Squibb Pharmaceutical Research Institute. He also worked for foundations such as the National Cancer Institute and the National Cancer Institute from 1988 to 1991. Clay has been hired by BioPharmaceuticals and Mirna Therapeutics, which are leading biotechnology companies. He serves the two organizations as a board member. Siegall was awarded a Bachelor of Science in Zoology degree from the University of Maryland, and he later enrolled at the George Washington University, where he graduated with a Ph.D. in Genetics.
Mirna Therapeutics chose Clay Siegall to serve it as an outside board member as from January 2013. He has sufficient experience in the pharmaceutical industry his expertise is highly needed by the company. Siegall played a significant role in the creation of micro-RNA-based therapeutics. He believes that the therapeutics are crucial in conducting cancer research. According to him, the scientists that have been hired by Mirna are highly productive. Clay was grateful for being chosen as an outside director of the firm. He has devoted himself to working with the company’s management to develop reliable cancer cures. Siegall has written various books, and he holds 15 patents for his work.